Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states h
AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable
Natali et al.'s systematic review across 10 medical specialties reveals a universal three-phase pattern: (1) AI assistance improves performance metrics while present, (2) extended AI use reduces opportunities for independent skill-building, and (3) performance degrades when AI becomes unavailable, d
Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients
Among Black patients receiving GLP-1 therapy, those with net worth above $1 million had a median BMI of 35.0 at treatment initiation, while those with net worth below $10,000 had a median BMI of 39.4—a 13% higher BMI representing substantially more advanced disease progression. This reveals that str
The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
The USPSTF's 2018 Grade B recommendation for adult obesity covers only intensive multicomponent behavioral interventions (≥12 sessions in year 1). While the 2018 review examined pharmacotherapy, it covered only orlistat, lower-dose liraglutide, phentermine-topiramate, naltrexone-bupropion, and lorca
Automation bias in medical imaging causes clinicians to anchor on AI output rather than conducting independent reads, increasing false-positive rates by up to 12 percent even among experienced readers
A controlled study of 27 radiologists performing mammography reads found that erroneous AI prompts increased false-positive recalls by up to 12 percentage points, with the effect persisting across experience levels. The mechanism is automation bias: radiologists anchor on AI output rather than condu
AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms: prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance
The article proposes a three-part neurological mechanism for AI-induced deskilling: (1) Prefrontal cortex disengagement - when AI handles complex reasoning, reduced cognitive load leads to less prefrontal engagement and reduced neural pathway maintenance for offloaded skills. (2) Hippocampal disenga
Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who d
Dopaminergic reinforcement of AI-assisted success creates motivational entrenchment that makes deskilling a behavioral incentive problem, not just a training design problem
Most clinical AI safety discussions focus on cognitive offloading (you stop practicing) and automation bias (you trust the AI). However, the dopaminergic reinforcement element is underappreciated. AI assistance produces reliable, positive outcomes (performance improvement) that create dopaminergic r
Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias
Before Massachusetts Medicaid (MassHealth) expanded GLP-1 coverage for obesity in January 2024, Black patients were 49% less likely and Hispanic patients were 47% less likely to be prescribed semaglutide or tirzepatide compared to White patients (adjusted odds ratios). After the coverage expansion,
Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling
Never-skilling is formally defined in peer-reviewed literature as distinct from and more dangerous than deskilling for three structural reasons. First, it is unrecoverable: deskilling allows clinicians to re-engage practice and rebuild atrophied skills, but never-skilling means foundational represen
Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tap
GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
GLP-1 receptor agonists suppress appetite as their primary mechanism, reducing caloric intake by 20-30%. This creates systematic micronutrient deficiency risk across iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C. The joint advisory from four major obesity/nutrition organiza
Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each
This systematic review identifies three mechanistically distinct pathways through which clinical AI degrades physician competence. **Deskilling** occurs when existing expertise atrophies through disuse: colonoscopy polyp detection dropped from 28.4% to 22.4% after 3 months of AI use, and experienced
GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics a
Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, a
GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
The joint advisory from OMA, ASN, ACLM, and The Obesity Society explicitly identifies food insecurity and nutrition insecurity as barriers to equitable obesity management with GLP-1s. The screening checklist includes food insecurity, nutrition insecurity, and housing/transportation challenges. The a
BMI fails as a malnutrition indicator in obese HFpEF patients because sarcopenic obesity allows high body fat and low muscle mass to coexist at BMI 30-plus
Among hospitalized HFpEF patients, 32.8% are obese, yet malnutrition is present even in patients with average BMI 33 kg/m². This occurs through sarcopenic obesity—the co-occurrence of low skeletal muscle mass with increased body fat. BMI measures total body mass relative to height but cannot disting
GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk
GLP-1 receptor agonists reduce HF hospitalization and mortality by 40%+ in obese HFpEF patients (STEP-HFpEF). However, this same population faces a hidden paradox: 32.8% of hospitalized HFpEF patients are obese, and among these obese patients (average BMI 33 kg/m²), many are malnourished with sarcop
Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
Never-skilling presents a unique detection challenge that distinguishes it from deskilling. When a physician loses existing skills through disuse (deskilling), the degradation is detectable through comparison to their previous baseline performance. But when a trainee never acquires foundational comp
GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macr
US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
The JACC inaugural Cardiovascular Statistics report documents that hypertension-related cardiovascular deaths nearly doubled from 23 to 43 per 100,000 population between 2000 and 2019, while treatment and control rates have remained stagnant for 15 years. Nearly 1 in 2 US adults meet current hyperte
Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
The STEER study (n=10,625 matched patients with overweight/obesity and ASCVD without diabetes) found semaglutide associated with 29% lower revised 3-point MACE versus tirzepatide (HR 0.71), 22% lower revised 5-point MACE, and in per-protocol analysis 43-57% reductions in favor of semaglutide. This f
GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained
Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
The SCORE study tracked 9,321 individuals with ASCVD and overweight/obesity (without diabetes) who initiated semaglutide 2.4mg, matched to 18,642 controls over mean 200-day follow-up. Semaglutide was associated with HR 0.43 for revised 3-point MACE and HR 0.55 for revised 5-point MACE (both p<0.001)
Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose
A Danish cohort study of an online weight-loss program combining behavioral support with individualized semaglutide dosing achieved 16.7% baseline weight loss over 64 weeks—matching STEP clinical trial outcomes of 15-17%—while using approximately half the typical drug dose. This finding suggests beh
Page 7 of 13